Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreWed, 10th Feb 2021 09:31
Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read more(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.
Read moreSyncona Investee Autolus To Focus On Adult Leukemia Programme in 2021
Read more(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.
Read moreUK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
Read moreSyncona Portfolio Companies Boost Interim Result; Launches New Company
Read more(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse
Read moreSyncona Investee Freeline Posts Widened Interim Loss On Higher Costs
Read more(Sharecast News) - Healthcare investment firm Syncona said on Friday that portfolio business Freeline Therapeutics had seen interim losses widen as a result of increased research and development costs.
Read moreUK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation
Read moreSyncona Life Science Portfolio Boosted By Autolus And Freeline
Read moreSyncona Investee Freeline Therapeutics Prices IPO In New York
Read more(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.
Read more